{"protocolSection": {"identificationModule": {"nctId": "NCT00885378", "orgStudyIdInfo": {"id": "CV181-080"}, "secondaryIdInfos": [{"id": "EUDRACT #: 2009-010224-25"}], "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus", "officialTitle": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2.5 mg Saxagliptin, Twice Daily, in Combination With Metformin IR in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin IR Alone"}, "statusModule": {"statusVerifiedDate": "2015-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-05"}, "primaryCompletionDateStruct": {"date": "2010-02", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-02", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-04-21", "studyFirstSubmitQcDate": "2009-04-21", "studyFirstPostDateStruct": {"date": "2009-04-22", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-11-02", "resultsFirstSubmitQcDate": "2011-11-14", "resultsFirstPostDateStruct": {"date": "2011-12-16", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-05-08", "lastUpdatePostDateStruct": {"date": "2015-06-01", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to compare the reduction in hemoglobin A1C (A1C) for participants taking saxagliptin in combination with metformin immediate release (IR) versus metformin IR alone."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 166, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Saxagliptin plus metformin IR", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Saxagliptin plus metformin IR"]}, {"label": "Placebo plus metformin IR", "type": "PLACEBO_COMPARATOR", "interventionNames": ["Drug: Placebo plus metformin IR"]}], "interventions": [{"type": "DRUG", "name": "Saxagliptin plus metformin IR", "description": "Tablets, Oral, 2.5 mg, Twice daily, 12 weeks", "armGroupLabels": ["Saxagliptin plus metformin IR"], "otherNames": ["BMS-477118", "Onglyza"]}, {"type": "DRUG", "name": "Placebo plus metformin IR", "description": "Tablets, Oral, Placebo, Twice daily, 12 weeks", "armGroupLabels": ["Placebo plus metformin IR"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Mean Hemoglobin A1C (A1c) and Change From Baseline to Week 12", "description": "Mean change was adjusted for baseline.", "timeFrame": "Baseline, Week 12"}], "secondaryOutcomes": [{"measure": "Mean Baseline and Change From Baseline in Fasting Plasma Glucose (FPG)", "description": "Mean change was adjusted for baseline.", "timeFrame": "Baseline, Week 12"}, {"measure": "Percentage of Participants Achieving a Therapeutic Glycemic Response (A1C < 7.0%) at Week 12", "description": "Adjusted for baseline. Calculated using the method by Zhang et al. (Zhang M, Tsiatis A, Davidian M. Improving efficiency of inference in randomized clinical trials using auxiliary covariates. Biometrics. Published online on January 11, 2008; Digital Object Identifier: 10.1111/j.1541-0420.2007.00976.x.)", "timeFrame": "Week 12"}, {"measure": "Percentage of Participants Achieving a Therapeutic Glycemic Response (A1C <= 6.5%) at Week 12", "description": "Adjusted for baseline. Calculated using the method by Zhang et al. (Zhang M, Tsiatis A, Davidian M. Improving efficiency of inference in randomized clinical trials using auxiliary covariates. Biometrics. Published online on January 11, 2008; Digital Object Identifier: 10.1111/j.1541-0420.2007.00976.x.)", "timeFrame": "Week 12"}], "otherOutcomes": [{"measure": "Participant Adverse Event (AE), Related AE, Serious Adverse Event (SAE), Related SAE, and Discontinued Due to AEs Summary", "description": "AE = any new untoward medical occurrence/worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment.SAE = any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Treatment-related=Possible, Probable, or Certain relationship to drug.", "timeFrame": "Week 1 to Week 12; AEs are included up to the last treatment day + 1 day or the last visit in the double-blind (DB) period. SAEs are included up to the last of 1) the last treatment day + 30 days or 2) the last visit day + 30 days in the DB period."}, {"measure": "Participants With Reported Hypoglycemia AEs During Double-Blind Treatment Period", "description": "Hypoglycemic Events are based upon the Saxagliptin Predefined List of Events, which included hypoglycemia, blood glucose decreased, and hypoglycemic unconsciousness.", "timeFrame": "Week 1 to Week 12; AEs are included up to the last treatment day + 1 day or the last visit in the DB period. SAEs are included up to the last of 1) the last treatment day + 30 days or 2) the last visit day + 30 days in the DB period."}, {"measure": "Participants With Confirmed Hypoglycemia", "description": "Confirmed hypoglycemia was defined by a fingerstick glucose value \\<= 50 mg/dL with associated hypoglycemia symptoms.", "timeFrame": "Week 1 to Week 12; AEs are included up to the last treatment day + 1 day or the last visit in the DB period. SAEs are included up to the last of 1) the last treatment day + 30 days or 2) the last visit day + 30 days in the DB period."}, {"measure": "Participant Electrocardiogram (ECG) Status at Baseline and Week 12", "description": "Abnormal ECGs were defined as those not within the normal limits for the participant, according to the investigator. 'Shifted Normal to Abnormal' and 'Shifted Abnormal to Normal' references a change from measurements at Baseline to those at Week 12.", "timeFrame": "Baseline, Week 12"}, {"measure": "Baseline and Mean Change From Baseline in Participant Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)", "description": "Baseline values reference the measurement for the cohort of participants evaluated at the given time point.", "timeFrame": "Baseline, Week 4, Week 8, Week 12"}, {"measure": "Baseline and Mean Change From Baseline in Participant Heart Rate (HR)", "description": "Baseline values reference the measurement for the cohort of participants evaluated at the given time point.", "timeFrame": "Baseline, Week 4, Week 8, Week 12"}, {"measure": "Participants Experiencing Changes From Baseline in Laboratory Parameters That Met the Marked Abnormality Criteria", "description": "A laboratory value was considered a marked abnormality if it is outside the pre-defined criteria for marked abnormality and the on-treatment value was more extreme (farther from the limit) than the baseline value. ULN=upper limit of normal; LLN=lower limit of normal.", "timeFrame": "Baseline, Week 12"}, {"measure": "Participants Experiencing Changes From Baseline in Urinalysis Parameters That Met the Marked Abnormality Criteria", "description": "Marked abnormality criteria were urine protein: if pre-Rx=o use \\>=2, if pre-Rx =0.5 or 1 use \\>=3, if pre-Rx =2, use \\>=4; urine blood: if pre-Rx=0, use \\>=2, if pre-Rx=0.5 or 1, use \\>=3, if pre-Rx=2, use \\>=4; Urine red blood cell count (RBC): if pre-Rx=o use \\>=2, if pre-Rx =0.5 or 1 use \\>=3, if pre-Rx =2, use \\>=4; urine white blood cell count (WBC): if pre-Rx=o use \\>=2, if pre-Rx =0.5 or 1 use \\>=3, if pre-Rx =2, use \\>=4.", "timeFrame": "Baseline, Week 12"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Type 2 diabetes\n* 18-78 years of age\n* Taking stable twice daily (BID) dosing of metformin IR (at least 1500 mg) for at least 8 weeks\n* A1C: 7-10%\n* C-peptide: \u2265 0.8 ng/mL\n* Body mass index (BMI): \u226445 kg/m\\^2\n\nExclusion Criteria:\n\n* Women of childbearing potential unable or unwilling to use acceptable birth control\n* Women who are pregnant or breastfeeding\n* Fasting plasma glucose (FPG) \\>270 mg/dL\n* Significant cardiovascular history\n* Symptoms of poorly controlled diabetes\n* History of diabetic ketoacidosis or hyperosmolar nonketotic coma\n* Insulin therapy within one year of screening\n* Cardiovascular even within the prior 6 months\n* New York Heart Association Stage III/IV congestive heart failure and/or known left ventricular ejection fraction \\<=40%\n* Significant history of renal or hepatic disease\n* History of a psychiatric disorder, alcohol or drug abuse within the previous year\n* Treatment with potent CYP3A4 inhibitors or inducers\n* Immunocompromised participants\n* Active liver disease or clinically significant abnormal hepatic, renal , endocrine, metabolic, or hematological screening tests", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "78 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Bristol-Myers Squibb", "affiliation": "Bristol-Myers Squibb", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "John Muir Physician Network Clinical Research Center", "city": "Concord", "state": "California", "zip": "94520", "country": "United States", "geoPoint": {"lat": 37.97798, "lon": -122.03107}}, {"facility": "Southland Clinical Research Center, Inc.", "city": "Fountain Valley", "state": "California", "zip": "92708", "country": "United States", "geoPoint": {"lat": 33.70918, "lon": -117.95367}}, {"facility": "Torrance Clinical Research", "city": "Lomita", "state": "California", "zip": "90717", "country": "United States", "geoPoint": {"lat": 33.79224, "lon": -118.31507}}, {"facility": "Ritchken & First M.D.'S", "city": "San Diego", "state": "California", "zip": "92117", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "Central Florida Clinical Trials, Inc.", "city": "Altamonte Springs", "state": "Florida", "zip": "32701", "country": "United States", "geoPoint": {"lat": 28.66111, "lon": -81.36562}}, {"facility": "Family Care Associates Of Nw Florida", "city": "Chipley", "state": "Florida", "zip": "32428", "country": "United States", "geoPoint": {"lat": 30.78186, "lon": -85.53854}}, {"facility": "Clinical Therapeutics Corporation", "city": "Coral Gables", "state": "Florida", "zip": "33134", "country": "United States", "geoPoint": {"lat": 25.72149, "lon": -80.26838}}, {"facility": "Nextphase Clinical Trials, Inc.", "city": "Miami", "state": "Florida", "zip": "33145", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Middle Georgia Drug Study Center, Llc", "city": "Perry", "state": "Georgia", "zip": "31069", "country": "United States", "geoPoint": {"lat": 32.45821, "lon": -83.73157}}, {"facility": "Louisiana Heart Center Research", "city": "Slidell", "state": "Louisiana", "zip": "70458", "country": "United States", "geoPoint": {"lat": 30.27519, "lon": -89.78117}}, {"facility": "Jackson Clinic", "city": "Rolling Fork", "state": "Mississippi", "zip": "39159", "country": "United States", "geoPoint": {"lat": 32.90652, "lon": -90.87816}}, {"facility": "Community Health Care Of Manchester", "city": "Akron", "state": "Ohio", "zip": "44319", "country": "United States", "geoPoint": {"lat": 41.08144, "lon": -81.51901}}, {"facility": "Midwest Regional Research, Inc.", "city": "Bellbrook", "state": "Ohio", "zip": "45305", "country": "United States", "geoPoint": {"lat": 39.63562, "lon": -84.07077}}, {"facility": "Wells Institute For Health Awareness", "city": "Kettering", "state": "Ohio", "zip": "45429", "country": "United States", "geoPoint": {"lat": 39.6895, "lon": -84.16883}}, {"facility": "Newark Physician Associates", "city": "Newark", "state": "Ohio", "zip": "43055", "country": "United States", "geoPoint": {"lat": 40.05812, "lon": -82.40126}}, {"facility": "Integris Family Care South", "city": "Oklahoma", "state": "Oklahoma", "zip": "73170", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Integris Family Care Yukon", "city": "Yukon", "state": "Oklahoma", "zip": "73099", "country": "United States", "geoPoint": {"lat": 35.50672, "lon": -97.76254}}, {"facility": "Williamette Valley Clinical Studies", "city": "Eugene", "state": "Oregon", "zip": "97404", "country": "United States", "geoPoint": {"lat": 44.05207, "lon": -123.08675}}, {"facility": "Integrated Medical Group Pc/Fleetwood Clinical Research", "city": "Fleetwood", "state": "Pennsylvania", "zip": "19522", "country": "United States", "geoPoint": {"lat": 40.45398, "lon": -75.81798}}, {"facility": "Southeastern Research Associates, Inc", "city": "Taylors", "state": "South Carolina", "zip": "29687", "country": "United States", "geoPoint": {"lat": 34.92039, "lon": -82.29623}}, {"facility": "Holston Medical Group", "city": "Kingsport", "state": "Tennessee", "zip": "37660", "country": "United States", "geoPoint": {"lat": 36.54843, "lon": -82.56182}}, {"facility": "Village Family Practice", "city": "Houston", "state": "Texas", "zip": "77024", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Southwest Clinical Research Centers, Llc", "city": "Pearland", "state": "Texas", "zip": "77584", "country": "United States", "geoPoint": {"lat": 29.56357, "lon": -95.28605}}, {"facility": "Jolene K. Berg, Md., Dgd Research, Inc.", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Tidewater Integrated Medical Research", "city": "Virginia Beach", "state": "Virginia", "zip": "23454", "country": "United States", "geoPoint": {"lat": 36.85293, "lon": -75.97799}}, {"facility": "Local Institution", "city": "Ludwigshafen", "zip": "67067", "country": "Germany", "geoPoint": {"lat": 49.48121, "lon": 8.44641}}, {"facility": "Local Institution", "city": "Magdeberg", "zip": "39112", "country": "Germany"}, {"facility": "Local Institution", "city": "Pirna", "zip": "01796", "country": "Germany", "geoPoint": {"lat": 50.95843, "lon": 13.93702}}, {"facility": "Local Institution", "city": "Saarbrucken", "zip": "66119", "country": "Germany", "geoPoint": {"lat": 49.23262, "lon": 7.0098}}, {"facility": "Local Institution", "city": "Saarlouis", "zip": "66740", "country": "Germany", "geoPoint": {"lat": 49.31366, "lon": 6.75154}}, {"facility": "Local Institution", "city": "Tann", "zip": "36142", "country": "Germany", "geoPoint": {"lat": 50.64284, "lon": 10.02385}}, {"facility": "Local Institution", "city": "Wuestensachsen", "zip": "36115", "country": "Germany"}, {"facility": "Local Institution", "city": "Balatonfured", "zip": "8230", "country": "Hungary", "geoPoint": {"lat": 46.96188, "lon": 17.87187}}, {"facility": "Local Institution", "city": "Budapest", "zip": "1036", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Local Institution", "city": "Eger", "zip": "3300", "country": "Hungary", "geoPoint": {"lat": 47.90265, "lon": 20.37329}}, {"facility": "Local Institution", "city": "Szigetvar", "zip": "7900", "country": "Hungary", "geoPoint": {"lat": 46.04865, "lon": 17.80554}}, {"facility": "Local Institution", "city": "Zalaegerszeg", "zip": "8900", "country": "Hungary", "geoPoint": {"lat": 46.84, "lon": 16.84389}}, {"facility": "Local Institution", "city": "Ponce", "zip": "00716", "country": "Puerto Rico", "geoPoint": {"lat": 18.01108, "lon": -66.61406}}, {"facility": "Local Institution", "city": "San Juan", "zip": "00909", "country": "Puerto Rico", "geoPoint": {"lat": 18.46633, "lon": -66.10572}}, {"facility": "Local Institution", "city": "San Juan", "zip": "00920", "country": "Puerto Rico", "geoPoint": {"lat": 18.46633, "lon": -66.10572}}, {"facility": "Local Institution", "city": "San Juan", "zip": "00926", "country": "Puerto Rico", "geoPoint": {"lat": 18.46633, "lon": -66.10572}}]}, "referencesModule": {"references": [{"pmid": "24565221", "type": "DERIVED", "citation": "White JL, Buchanan P, Li J, Frederich R. A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy. BMC Endocr Disord. 2014 Feb 24;14:17. doi: 10.1186/1472-6823-14-17."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Of the 166 subjects who entered the lead-in period, 6 discontinued: 3 withdrawal of consent, 1 poor/noncompliance, 1 adverse event (AE; abdominal pain secondary to partial small bowel obstruction), and 1 elevated liver enzymes that did not meet study exclusion criteria but was discontinued by the investigator.", "recruitmentDetails": "Participants at 43 sites in 4 countries (25 sites in the United States \\[US\\], 9 in Germany, 5 in Hungary, and 4 in Puerto Rico) received study medication and participated in this study.", "groups": [{"id": "FG000", "title": "Saxagliptin 2.5 mg + Metformin Immediate Release (IR)", "description": "Saxagliptin 2.5 mg tablets orally (PO) plus a flexible metformin IR dose twice daily (BID)."}, {"id": "FG001", "title": "Placebo + Metformin IR", "description": "2.5 mg placebo tablets PO BID plus flexible metformin IR dose."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Number randomized.", "numSubjects": "74"}, {"groupId": "FG001", "comment": "Number randomized.", "numSubjects": "86"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "66"}, {"groupId": "FG001", "numSubjects": "78"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "8"}]}], "dropWithdraws": [{"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Poor/Noncompliance", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Saxagliptin 2.5 mg + Metformin Immediate Release (IR)", "description": "Saxagliptin 2.5 mg tablets orally (PO) plus a flexible metformin IR dose twice daily (BID)."}, {"id": "BG001", "title": "Placebo + Metformin IR", "description": "2.5 mg placebo tablets PO BID plus flexible metformin IR dose."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "74"}, {"groupId": "BG001", "value": "86"}, {"groupId": "BG002", "value": "160"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "53.90", "spread": "10.35"}, {"groupId": "BG001", "value": "56.60", "spread": "9.97"}, {"groupId": "BG002", "value": "55.4", "spread": "10.20"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "34"}, {"groupId": "BG001", "value": "41"}, {"groupId": "BG002", "value": "75"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "40"}, {"groupId": "BG001", "value": "45"}, {"groupId": "BG002", "value": "85"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "4"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "11"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "64"}, {"groupId": "BG001", "value": "80"}, {"groupId": "BG002", "value": "144"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "49"}, {"groupId": "BG001", "value": "56"}, {"groupId": "BG002", "value": "105"}]}]}, {"title": "Hungary", "categories": [{"measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "16"}]}]}, {"title": "Puerto Rico", "categories": [{"measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "18"}]}]}, {"title": "Germany", "categories": [{"measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "21"}]}]}]}, {"title": "Mean Height", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "cm", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "168.38", "spread": "9.56"}, {"groupId": "BG001", "value": "167.77", "spread": "8.99"}, {"groupId": "BG002", "value": "168.05", "spread": "9.23"}]}]}]}, {"title": "Mean Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "95.85", "spread": "21.40"}, {"groupId": "BG001", "value": "91.74", "spread": "19.87"}, {"groupId": "BG002", "value": "93.64", "spread": "20.63"}]}]}]}, {"title": "Mean Body Mass Index (BMI)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg / m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "33.68", "spread": "5.94"}, {"groupId": "BG001", "value": "32.51", "spread": "6.18"}, {"groupId": "BG002", "value": "33.05", "spread": "6.08"}]}]}]}, {"title": "Participant Body Mass Index", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "< 30 kg / m^2", "categories": [{"measurements": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "35"}, {"groupId": "BG002", "value": "54"}]}]}, {"title": ">= 30 kg / m^2", "categories": [{"measurements": [{"groupId": "BG000", "value": "55"}, {"groupId": "BG001", "value": "51"}, {"groupId": "BG002", "value": "106"}]}]}]}, {"title": "Mean Duration of Type 2 Diabetes Mellitus", "description": "Mean time since the time of diagnosis of Type 2 Diabetes Mellitus.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "5.81", "spread": "6.37"}, {"groupId": "BG001", "value": "6.17", "spread": "4.21"}, {"groupId": "BG002", "value": "6.00", "spread": "5.30"}]}]}]}, {"title": "Mean Metformin Dose at Baseline", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1911.5", "spread": "376.59"}, {"groupId": "BG001", "value": "1855.8", "spread": "330.19"}, {"groupId": "BG002", "value": "1881.6", "spread": "352.38"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "SECONDARY", "title": "Mean Baseline and Change From Baseline in Fasting Plasma Glucose (FPG)", "description": "Mean change was adjusted for baseline.", "populationDescription": "Randomized participants with a measurement at the specified timepoint with Last Observation Carried Forward (LOCF).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg / dL", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Saxagliptin 2.5 mg + Metformin Immediate Release (IR)", "description": "Saxagliptin 2.5 mg tablets orally (PO) plus a flexible metformin IR dose twice daily (BID)."}, {"id": "OG001", "title": "Placebo + Metformin IR", "description": "2.5 mg placebo tablets PO BID plus flexible metformin IR dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "73"}, {"groupId": "OG001", "value": "84"}]}], "classes": [{"title": "Mean Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "164.22", "spread": "5.512"}, {"groupId": "OG001", "value": "161.25", "spread": "4.624"}]}]}, {"title": "Adjusted Mean Change from Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-13.73", "spread": "4.51"}, {"groupId": "OG001", "value": "-4.22", "spread": "4.20"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1248", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model: post - pre = pretreatment.", "paramType": "Mean Difference (Final Values)", "paramValue": "-9.51", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-21.68", "ciUpperLimit": "2.66", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "6.162", "estimateComment": "Estimate = adjusted mean change for Saxagliptin - adjusted mean change for Placebo."}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving a Therapeutic Glycemic Response (A1C < 7.0%) at Week 12", "description": "Adjusted for baseline. Calculated using the method by Zhang et al. (Zhang M, Tsiatis A, Davidian M. Improving efficiency of inference in randomized clinical trials using auxiliary covariates. Biometrics. Published online on January 11, 2008; Digital Object Identifier: 10.1111/j.1541-0420.2007.00976.x.)", "populationDescription": "Randomized participants with measurement at timepoint with LOCF.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Saxagliptin 2.5 mg + Metformin Immediate Release (IR)", "description": "Saxagliptin 2.5 mg tablets orally (PO) plus a flexible metformin IR dose twice daily (BID)."}, {"id": "OG001", "title": "Placebo + Metformin IR", "description": "2.5 mg placebo tablets PO BID plus flexible metformin IR dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "73"}, {"groupId": "OG001", "value": "84"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "37.5", "lowerLimit": "27.4", "upperLimit": "47.6"}, {"groupId": "OG001", "value": "24.2", "lowerLimit": "15.8", "upperLimit": "32.7"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Final Values)", "paramValue": "13.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.1", "ciUpperLimit": "25.4", "estimateComment": "Adjusted for baseline."}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving a Therapeutic Glycemic Response (A1C <= 6.5%) at Week 12", "description": "Adjusted for baseline. Calculated using the method by Zhang et al. (Zhang M, Tsiatis A, Davidian M. Improving efficiency of inference in randomized clinical trials using auxiliary covariates. Biometrics. Published online on January 11, 2008; Digital Object Identifier: 10.1111/j.1541-0420.2007.00976.x.)", "populationDescription": "Randomized participants with measurement at timepoint with LOCF.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Saxagliptin 2.5 mg + Metformin Immediate Release (IR)", "description": "Saxagliptin 2.5 mg tablets orally (PO) plus a flexible metformin IR dose twice daily (BID)."}, {"id": "OG001", "title": "Placebo + Metformin IR", "description": "2.5 mg placebo tablets PO BID plus flexible metformin IR dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "74"}, {"groupId": "OG001", "value": "84"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "24.6", "lowerLimit": "15.1", "upperLimit": "34.1"}, {"groupId": "OG001", "value": "10.7", "lowerLimit": "4.6", "upperLimit": "16.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Final Values)", "paramValue": "13.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "3.0", "ciUpperLimit": "24.7", "estimateComment": "Adjusted for baseline."}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Participant Adverse Event (AE), Related AE, Serious Adverse Event (SAE), Related SAE, and Discontinued Due to AEs Summary", "description": "AE = any new untoward medical occurrence/worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment.SAE = any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Treatment-related=Possible, Probable, or Certain relationship to drug.", "populationDescription": "All treated participants.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Week 1 to Week 12; AEs are included up to the last treatment day + 1 day or the last visit in the double-blind (DB) period. SAEs are included up to the last of 1) the last treatment day + 30 days or 2) the last visit day + 30 days in the DB period.", "groups": [{"id": "OG000", "title": "Saxagliptin 2.5 mg + Metformin Immediate Release (IR)", "description": "Saxagliptin 2.5 mg tablets orally (PO) plus a flexible metformin IR dose twice daily (BID)."}, {"id": "OG001", "title": "Placebo + Metformin IR", "description": "2.5 mg placebo tablets PO BID plus flexible metformin IR dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "74"}, {"groupId": "OG001", "value": "86"}]}], "classes": [{"title": "At Least 1 AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "34"}]}]}, {"title": "At Least 1 Related AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "Deaths", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "At Least 1 SAE", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "At Least 1 Related SAE", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Discontinued Due to SAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Discontinued Due to AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Participants With Reported Hypoglycemia AEs During Double-Blind Treatment Period", "description": "Hypoglycemic Events are based upon the Saxagliptin Predefined List of Events, which included hypoglycemia, blood glucose decreased, and hypoglycemic unconsciousness.", "populationDescription": "All treated participants.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Week 1 to Week 12; AEs are included up to the last treatment day + 1 day or the last visit in the DB period. SAEs are included up to the last of 1) the last treatment day + 30 days or 2) the last visit day + 30 days in the DB period.", "groups": [{"id": "OG000", "title": "Saxagliptin 2.5 mg + Metformin Immediate Release (IR)", "description": "Saxagliptin 2.5 mg tablets orally (PO) plus a flexible metformin IR dose twice daily (BID)."}, {"id": "OG001", "title": "Placebo + Metformin IR", "description": "2.5 mg placebo tablets PO BID plus flexible metformin IR dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "74"}, {"groupId": "OG001", "value": "86"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "1"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Participants With Confirmed Hypoglycemia", "description": "Confirmed hypoglycemia was defined by a fingerstick glucose value \\<= 50 mg/dL with associated hypoglycemia symptoms.", "populationDescription": "All treated participants.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Week 1 to Week 12; AEs are included up to the last treatment day + 1 day or the last visit in the DB period. SAEs are included up to the last of 1) the last treatment day + 30 days or 2) the last visit day + 30 days in the DB period.", "groups": [{"id": "OG000", "title": "Saxagliptin 2.5 mg + Metformin Immediate Release (IR)", "description": "Saxagliptin 2.5 mg tablets orally (PO) plus a flexible metformin IR dose twice daily (BID)."}, {"id": "OG001", "title": "Placebo + Metformin IR", "description": "2.5 mg placebo tablets PO BID plus flexible metformin IR dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "74"}, {"groupId": "OG001", "value": "86"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Participant Electrocardiogram (ECG) Status at Baseline and Week 12", "description": "Abnormal ECGs were defined as those not within the normal limits for the participant, according to the investigator. 'Shifted Normal to Abnormal' and 'Shifted Abnormal to Normal' references a change from measurements at Baseline to those at Week 12.", "populationDescription": "All treated participants, excluding those with missing values.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Saxagliptin 2.5 mg + Metformin Immediate Release (IR)", "description": "Saxagliptin 2.5 mg tablets orally (PO) plus a flexible metformin IR dose twice daily (BID)."}, {"id": "OG001", "title": "Placebo + Metformin IR", "description": "2.5 mg placebo tablets PO BID plus flexible metformin IR dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "78"}]}], "classes": [{"title": "Baseline Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "42"}]}]}, {"title": "Baseline Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "36"}]}]}, {"title": "Week 12 Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "50"}]}]}, {"title": "Week 12 Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "28"}]}]}, {"title": "Shifted Normal to Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "4"}]}]}, {"title": "Shifted Abnormal to Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "12"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Baseline and Mean Change From Baseline in Participant Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)", "description": "Baseline values reference the measurement for the cohort of participants evaluated at the given time point.", "populationDescription": "All treated participants. n= number of participants with measurement at time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline, Week 4, Week 8, Week 12", "groups": [{"id": "OG000", "title": "Saxagliptin 2.5 mg + Metformin Immediate Release (IR)", "description": "Saxagliptin 2.5 mg tablets orally (PO) plus a flexible metformin IR dose twice daily (BID)."}, {"id": "OG001", "title": "Placebo + Metformin IR", "description": "2.5 mg placebo tablets PO BID plus flexible metformin IR dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "74"}, {"groupId": "OG001", "value": "86"}]}], "classes": [{"title": "Baseline SBP for Week 4 cohort (n=74, 84)", "categories": [{"measurements": [{"groupId": "OG000", "value": "128.89", "spread": "1.67"}, {"groupId": "OG001", "value": "127.57", "spread": "1.53"}]}]}, {"title": "Baseline DBP for Week 4 cohort (n=74, 84)", "categories": [{"measurements": [{"groupId": "OG000", "value": "78.99", "spread": "1.07"}, {"groupId": "OG001", "value": "77.07", "spread": "1.05"}]}]}, {"title": "SBP Change From Baseline at Week 4 (n=74, 84)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.47", "spread": "1.43"}, {"groupId": "OG001", "value": "0.17", "spread": "1.16"}]}]}, {"title": "DBP Change From Baseline at Week 4 (n=74, 84)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.81", "spread": "0.84"}, {"groupId": "OG001", "value": "0.95", "spread": "0.86"}]}]}, {"title": "Baseline SBP for Week 8 cohort (n=70, 81)", "categories": [{"measurements": [{"groupId": "OG000", "value": "128.33", "spread": "1.67"}, {"groupId": "OG001", "value": "127.60", "spread": "1.57"}]}]}, {"title": "Baseline DBP for Week 8 cohort (n=70, 81)", "categories": [{"measurements": [{"groupId": "OG000", "value": "78.87", "spread": "1.08"}, {"groupId": "OG001", "value": "77.32", "spread": "1.03"}]}]}, {"title": "SBP Change From Baseline at Week 8 (n=70, 81)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.60", "spread": "1.66"}, {"groupId": "OG001", "value": "-0.43", "spread": "1.48"}]}]}, {"title": "DBP Change From Baseline at Week 8 (n=70, 81)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.37", "spread": "0.94"}, {"groupId": "OG001", "value": "0.86", "spread": "0.93"}]}]}, {"title": "Baseline SBP for Week 12 cohort (n=66, 77)", "categories": [{"measurements": [{"groupId": "OG000", "value": "128.18", "spread": "1.76"}, {"groupId": "OG001", "value": "127.38", "spread": "1.56"}]}]}, {"title": "Baseline DBP for Week 12 cohort (n=66, 77)", "categories": [{"measurements": [{"groupId": "OG000", "value": "78.85", "spread": "1.13"}, {"groupId": "OG001", "value": "77.23", "spread": "1.06"}]}]}, {"title": "SBP Change From Baseline at Week 12 (n=66, 77)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.59", "spread": "1.51"}, {"groupId": "OG001", "value": "0.83", "spread": "1.26"}]}]}, {"title": "DBP Change From Baseline at Week 12 (n=66, 77)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.03", "spread": "0.75"}, {"groupId": "OG001", "value": "1.29", "spread": "0.85"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Baseline and Mean Change From Baseline in Participant Heart Rate (HR)", "description": "Baseline values reference the measurement for the cohort of participants evaluated at the given time point.", "populationDescription": "All treated participants. n= number of participants with measurement at time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline, Week 4, Week 8, Week 12", "groups": [{"id": "OG000", "title": "Saxagliptin 2.5 mg + Metformin Immediate Release (IR)", "description": "Saxagliptin 2.5 mg tablets orally (PO) plus a flexible metformin IR dose twice daily (BID)."}, {"id": "OG001", "title": "Placebo + Metformin IR", "description": "2.5 mg placebo tablets PO BID plus flexible metformin IR dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "74"}, {"groupId": "OG001", "value": "86"}]}], "classes": [{"title": "Baseline HR for Week 4 cohort (n=74, 84)", "categories": [{"measurements": [{"groupId": "OG000", "value": "73.45", "spread": "1.072"}, {"groupId": "OG001", "value": "73.77", "spread": "0.968"}]}]}, {"title": "HR Change From Baseline at Week 4 (n=74, 84)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.97", "spread": "0.881"}, {"groupId": "OG001", "value": "1.18", "spread": "0.778"}]}]}, {"title": "Baseline HR for Week 8 cohort (n=70, 81)", "categories": [{"measurements": [{"groupId": "OG000", "value": "73.51", "spread": "1.091"}, {"groupId": "OG001", "value": "73.56", "spread": "0.990"}]}]}, {"title": "HR Change From Baseline at Week 8 (n=70, 81)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.70", "spread": "0.914"}, {"groupId": "OG001", "value": "0.28", "spread": "0.727"}]}]}, {"title": "Baseline HR for Week 12 cohort (n=66, 77)", "categories": [{"measurements": [{"groupId": "OG000", "value": "73.71", "spread": "1.142"}, {"groupId": "OG001", "value": "73.55", "spread": "1.035"}]}]}, {"title": "HR Change From Baseline at Week 12 (n=66, 77)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.61", "spread": "1.061"}, {"groupId": "OG001", "value": "0.60", "spread": "0.866"}]}]}]}, {"type": "PRIMARY", "title": "Mean Hemoglobin A1C (A1c) and Change From Baseline to Week 12", "description": "Mean change was adjusted for baseline.", "populationDescription": "Randomized participants with both a baseline value and post-baseline value (up to Week 12).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of glycosylated hemoglobins", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Saxagliptin 2.5 mg + Metformin Immediate Release (IR)", "description": "Saxagliptin 2.5 mg tablets orally (PO) plus a flexible metformin IR dose twice daily (BID)."}, {"id": "OG001", "title": "Placebo + Metformin IR", "description": "2.5 mg placebo tablets PO BID plus flexible metformin IR dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "74"}, {"groupId": "OG001", "value": "84"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.92", "spread": "0.11"}, {"groupId": "OG001", "value": "7.97", "spread": "0.09"}]}]}, {"title": "Adjusted Mean Change From Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.56", "spread": "0.09"}, {"groupId": "OG001", "value": "-0.22", "spread": "0.08"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0063", "pValueComment": "Between-group comparisons significant at alpha = 0.05, significance testing based on hierarchical testing.", "statisticalMethod": "ANCOVA", "statisticalComment": "Adjusted mean difference for saxagliptin groups vs placebo at Week 12(LOCF) was adjusted for baseline.", "paramType": "Standard Error of the Mean", "paramValue": "-0.34", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.58", "ciUpperLimit": "-0.10", "estimateComment": "difference between week t value - baseline value = baseline value + treatment."}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Participants Experiencing Changes From Baseline in Laboratory Parameters That Met the Marked Abnormality Criteria", "description": "A laboratory value was considered a marked abnormality if it is outside the pre-defined criteria for marked abnormality and the on-treatment value was more extreme (farther from the limit) than the baseline value. ULN=upper limit of normal; LLN=lower limit of normal.", "populationDescription": "All treated participants.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Saxagliptin 2.5 mg + Metformin Immediate Release (IR)", "description": "Saxagliptin 2.5 mg tablets orally (PO) plus a flexible metformin IR dose twice daily (BID)."}, {"id": "OG001", "title": "Placebo + Metformin IR", "description": "2.5 mg placebo tablets PO BID plus flexible metformin IR dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "74"}, {"groupId": "OG001", "value": "86"}]}], "classes": [{"title": "Hemoglobin < 8 g/dL", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Hematocrit < 0.75 prior to dosing", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Platelets < 50 x 10^9 c/L", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Platelets > 1.5 x ULN", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Leukocytes < 2 x 10^3 c/uL", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Neutrophils < 1 x 10^3 c/uL", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Eosinophils > 0.9 x 10^3 c/uL", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Lymphocytes <= 0.75 x 10^3 c/uL", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Alkaline Phosphatase >3x prior to dosing and > ULN", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Aspartate Aminotransferase > 3x ULN", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Aspartate Aminotransferase > 5x ULN", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Alanine Aminotransferase > 3x ULN", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Alanine Aminotransferase > 5x ULN", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Total Bilirubin > 2 mg/dL", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Total Bilirubin > 1.5x ULN", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Blood Urea Nitrogen > 2x prior to dosing and > ULN", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Creatinine > 2.5 mg/dL", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Serum Sodium <0.9x pre-Rx and <= 130 mEq/", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Serum Sodium >1.1x pre-Rx and >= 150 mEq/L", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Serum Potassium <=0.8x pre-Rx and <= 3.2 mEq/L", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Serum Potassium >=1.2x pre-Rx and >= 6.0 mEq/L", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Serum Chloride <90 mEq/L", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Serum Chloride > 120 mEq/L", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Albumin <0.9x LLN, or if pre-Rx<LLN use <0.75x", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Creatinine Kinase > 5x ULN", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Fasting Plasma Glucose < 50 mg/dL", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Fasting Plasma Glucose > 500 mg/dL", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Plasma Glucose Unspecified < 50 mg/dL", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Plasma Glucose Unspecified > 500 mg/dL", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Participants Experiencing Changes From Baseline in Urinalysis Parameters That Met the Marked Abnormality Criteria", "description": "Marked abnormality criteria were urine protein: if pre-Rx=o use \\>=2, if pre-Rx =0.5 or 1 use \\>=3, if pre-Rx =2, use \\>=4; urine blood: if pre-Rx=0, use \\>=2, if pre-Rx=0.5 or 1, use \\>=3, if pre-Rx=2, use \\>=4; Urine red blood cell count (RBC): if pre-Rx=o use \\>=2, if pre-Rx =0.5 or 1 use \\>=3, if pre-Rx =2, use \\>=4; urine white blood cell count (WBC): if pre-Rx=o use \\>=2, if pre-Rx =0.5 or 1 use \\>=3, if pre-Rx =2, use \\>=4.", "populationDescription": "All treated participants. N = number of participants analyzed and n = the number of participants with values available for each specific measurement.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Saxagliptin 2.5 mg + Metformin Immediate Release (IR)", "description": "Saxagliptin 2.5 mg tablets orally (PO) plus a flexible metformin IR dose twice daily (BID)."}, {"id": "OG001", "title": "Placebo + Metformin IR", "description": "2.5 mg placebo tablets PO BID plus flexible metformin IR dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "74"}, {"groupId": "OG001", "value": "86"}]}], "classes": [{"title": "Urine Protein (n=74, 84)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Urine Blood (n=74, 84)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Urine Red Blood Cells (n=7, 10)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Urine White Blood Cells (n=16, 18)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Placebo + Metformin IR", "description": "2.5 mg placebo tablets PO BID plus flexible metformin IR dose.", "seriousNumAffected": 1, "seriousNumAtRisk": 86, "otherNumAffected": 0, "otherNumAtRisk": 86}, {"id": "EG001", "title": "Saxagliptin 2.5 mg + Metformin Immediate Release (IR)", "description": "Saxagliptin 2.5 mg tablets orally (PO) plus a flexible metformin IR dose twice daily (BID).", "seriousNumAffected": 1, "seriousNumAtRisk": 74, "otherNumAffected": 0, "otherNumAtRisk": 74}], "seriousEvents": [{"term": "MYOCARDIAL INFARCTION", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 86}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 74}]}, {"term": "BACK PAIN", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 86}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 74}]}, {"term": "PULMONARY OEDEMA", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 86}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 74}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period \u2264 60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication."}, "pointOfContact": {"title": "Boaz Hirschberg", "organization": "AstraZeneca Pharmaceuticals", "email": "ClinicalTrialTransparency@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Mexico"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000502994", "term": "Saxagliptin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M228152", "name": "Saxagliptin", "asFound": "Manufacturer", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}